|Bid||31.20 x 14500|
|Ask||31.60 x 13900|
|Day's range||31.00 - 33.00|
|52-week range||17.60 - 34.60|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||131.47|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2019 financial results and provided its full-year 2020 net sales and adjusted EBITDA guidance.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another option for people living with cystinosis, in addition to the currently available PROCYSBI capsules.
Horizon Therapeutics plc (Nasdaq: HZNP) and Uplifting Athletes today announced a new partnership for the 2020 Reps for Rare Disease campaign, which offers an opportunity for NFL Draft prospects to give back and support the rare disease community. Participants who team up with Uplifting Athletes will dedicate their performance in one event – bench press, vertical jump or broad jump – at the NFL Scouting Combine or their school’s official pro day, to raising funds for rare disease research and awareness initiatives.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the first quarter with additional terms of the purchase not disclosed. Horizon is expected to occupy the campus in the second half of this year.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive officer.
The New England Journal of Medicine published Phase 3 trial data for Horizon Therapeutics’ TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease.
Horizon Therapeutics today announced that the FDA has approved TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
On a per-share basis, the Dublin-based company said it had a loss of 19 cents. Earnings, adjusted for non-recurring costs, came to 30 cents per share. The results surpassed Wall Street expectations. The ...
A tiny, little-known government agency is ramping up regulation of Canada's pharmaceutical industry, seeking to rein in prices for patented drugs that are among the highest in the world, according to industry sources and a Reuters analysis of government data. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs, including a rare-disease medication made by Horizon Pharma that can cost C$325,000 ($253,409) a year, documents reviewed by Reuters shows. The agency can challenge the list price of any patented drug in Canada and order companies to repay some revenue.